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Abstract	[213	words]	
Background:	Late-onset	non-infectious	pulmonary	complications	 (LONIPCs)	affect	6%	of	allogeneic	
stem	 cell	 transplantation	 (SCT)	 recipients	 within	 5	 years,	 conferring	 subsequent	 5-year	 survival	 of	
50%.	 Lung	 transplantation	 (LTx)	 is	 rarely	 performed	 in	 this	 setting	 due	 to	 concomitant	 extra-
pulmonary	morbidity,	excessive	immunosuppression	and	concerns	about	recurring	malignancy	being	
considered	contraindications.	This	study	assesses	survival	 in	highly	selected	patients	undergoing	LTx	
for	LONIPCs	after	SCT.		
	
Methods:	SCT	patients	undergoing	LTx	at	20	European	centres	between	1996-2014	were	included.	
Clinical	 data	 pre-	 and	 post	 LTx	were	 reviewed.	Propensity	 score	matched	 controls	were	 generated	
from	 the	 Eurotransplant	 and	 Scandiatransplant	 registries.	 Kaplan	 Meier	 survival	 analysis	 and	 Cox	
proportional	hazard	regression	models	evaluating	predictors	of	graft	loss	were	performed.		
	
Results:	Graft	survival	at	1,	3	and	5	years	was	84,	72	and	67%	among	the	105	SCT	patients	proved	
comparable	 to	 controls	 (p=0.75).	 Sepsis	 accounted	 for	 15/37	 (41%)	 deaths,	 with	 prior	 mechanical	
ventilation	 (HR	6.9	 (95%CI	 1.0	 –	 46.7);	p<0.001)	 the	 leading	 risk	 factor.	No	 SCT-specific	 risk-factors	
were	identified.	Recurring	malignancy	occurred	in	4	(4%)	patients.	LTx	≤2	years	post-SCT	increased	all-
cause	1-year	mortality	(HR	7.5	(95%CI	2.3-23.8;	p=0.001).		
	
Conclusions:	LTx	outcomes	following	SCT	were	comparable	to	other	end-stage	diseases.	LTx	should	
be	 considered	 feasible	 in	 selected	 candidates.	 No	 SCT-specific	 factors	 influencing	 outcome	 were	
identified	within	this	carefully	selected	patient	cohort.		 	
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Introduction	[399	words]	
	
Allogeneic	hematopoietic	stem	cell	transplantation	(SCT)	represents	an	established	treatment	option	
for	an	increasing	number	of	benign	and	malignant	diseases,	with	procedure	rates	exceeding	8000	in	
the	 United	 States	 and	 14,500	 in	 Europe	 annually	 (1).	 Leading	 indications	 include	 acute	 myeloid	
leukaemia	(AML)	and	acute	lymphocytic	leukaemia	(ALL),	which	currently	account	for	35%	and	16%	of	
procedures	respectively.	Although	refinements	in	SCT	protocols	have	improved	early	outcomes,	late-
onset	 non-infectious	 pulmonary	 complications	 (LONIPCs)	 continue	 to	 limit	 long-term	 survival	 (2).	
LONIPCs	occur	 in	20%	of	SCT	patients	and	encompass	 the	entire	 spectrum	of	 lung	disease,	 ranging	
from	interstitial	 lung	disease,	pleuroparenchymal	fibroelastosis	to	pulmonary	veno-occlusive	disease	
and	classical	bronchiolitis	obliterans	(BO)	(3).	Although	the	latter	has	long	been	considered	ubiquitous	
for	 pulmonary	 graft	 vs.	 host	 disease	 (pGvHD),	 recent	 studies	 suggest	 additional	 interstitial	 lung	
involvement	in	some	patients	(4,	5).	Treatment	strategies	ranging	from	oral	macrolides	to	intensified	
immunosuppression	 and	 extracorporeal	 photopheresis	 have	 demonstrated	 benefit,	 but	 outcomes	
remain	unpredictable	and	response	rates	disappointing	(6-8).		
Lung	transplantation	(LTx)	is	considered	viable	treatment	in	highly	selected	patients	with	various	end-
stage	lung	diseases.	Since	1995,	over	47,000	adult	LTx	procedures	worldwide	have	been	reported	to	
the	 International	 Society	 for	Heart	 and	 Lung	Transplantation	 (ISHLT),	with	emphysema	 (38%)	being	
the	 leading	 indication	 (9).	 Reports	 of	 LTx	 for	 LONIPCs	 extend	 as	 far	 back	 as	 1992	 (10),	 but	 data	 is	
extremely	limited.	Of	the	450	LTx	(1.1%)	performed	for	obliterative	bronchiolitis	in	the	past	20	years,	
only	65	were	attributed	to	LONIPCs.	
Shortages	 in	 suitable	 donor	 lungs	 universally	 limits	 transplant	 activity,	 with	many	 regions	 adopting	
weighted	scoring	systems	such	as	the	Lung	Allocation	Score	(LAS)	that	focus	on	disease-related	early	
survival	probability,	calculated	from	existing	United	Network	for	Organ	Sharing	(UNOS)	registry	data	
(11).	 Inevitably,	 this	 discourages	 LTx	 in	 orphan	 diseases	 along	with	 conditions	 of	 poorer	 predicted	
outcome.	Given	SCT	volume	and	the	projected	incidence	of	LONIPCs,	LTx	rates	are	much	lower	than	
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anticipated.	 Published	 experience	 is	 limited	 to	 case	 series	 and	 small	 cohorts	with	mixed	 outcomes	
leading	to	a	common	perception	that	LONIPCs	candidates	are	“high-risk”	(12-14),	with	peri-operative	
sepsis	 due	 to	 excessive	 prior	 immunosuppression,	 complications	 of	 previous	 long-term	 steroid	
treatment,	existing	microbial	colonization	and	the	ever-present	risk	of	recurring,	primary	malignancy	
being	cited	as	potential	pit-falls	(14).			
The	aim	of	 this	 study	 is	 to	quantify	 these	 risks	and	evaluate	LTx	outcomes	 in	carefully	 selected	SCT	
patients	 with	 LONIPCs	 in	 a	 large	 multi-centre	 cohort,	 paying	 particular	 attention	 to	 peri-operative	
sepsis	and	recurring	primary	malignancy.	
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Methods	[458	words]	
	
All	 patients	 undergoing	 LTx	 for	 LONIPCs	 following	 allogenic	 SCT	 at	 20	 European	 centres	 between	
1996-2014	 were	 retrospectively	 analysed.	 Clinical	 data	 pertaining	 to	 patient	 demographics,	 SCT	
treatment	protocols,	GvHD	incidence	and	subsequent	management	were	collated,	along	with	imaging	
and	 native	 lung	 histology	 data	 prior	 to	 LTx.	 Subsequent	 LTx	 follow-up	 data	 until	 30.06.2016	 was	
standardized	using	detailed	reporting	protocols.		
Autologous	SCT,	living-donor	lobar	LTx	following	SCT	from	the	same	donor	and	SCT	patients	with	LTx	
indications	 other	 than	 LONIPCs,	 such	 as	 smoking-related	 emphysema,	were	 excluded.	 Life-long	 LTx	
centre	follow-up	with	a	minimum	of	twice-yearly	review	was	mandatory.		
SCT	 were	 considered	 as	 being	 bone	marrow	 transplantations	 (BMT)	 or	 peripheral	 blood	 stem	 cell	
transplants	(PBSC)	using	accepted	definitions	(15,	16).	
Spirometry	adhered	to	ATS/ERS	guidelines	and	was	performed	at	each	attendance	in	all	centres	(17,	
18).	 Baseline	 forced	 expiratory	 volume	 in	 1	 second	 (FEV1)	 and	 forced	 vital	 capacity	 (FVC)	 after	 LTx	
were	calculated	from	the	mean	of	the	two	highest	values	recorded	a	minimum	of	3	weeks	apart	from	
one	another.	Diagnosis	of	chronic	lung	allograft	dysfunction	(CLAD)	required	a	≥3-week	loss	in	FEV1	of	
≤80%	baseline	in	the	absence	of	an	alternative	cause.	Sub-classification	into	obstructive	bronchiolitis	
obliterans	syndrome	(BOS)	or	restrictive	CLAD	(rCLAD)	adhered	to	currently	proposed	definitions	(19-
21).		
A	matched	 control	 cohort	 of	 non-SCT	 LTx	 recipients	was	 generated	 from	 the	 entire	 Eurotransplant	
and	 Scandiatransplant	 registries	 for	 1st	 LTx	 between	 1996-2014	 to	 compare	 LTx	 graft	 survival.	
Propensity	 score	matching	 for	gender,	age	at	 LTx,	 LTx	year,	 LTx	procedure	 (single	or	bilateral	graft)	
and	patient	admission	status	at	LTx	was	performed	using	 logistic	 regression	with	nearest	neighbour	
matching,	 a	0.2	 calliper	and	a	1:50	matching	 ratio.	Kaplan-Meier	 survival	 curves	 for	overall	 graft	 as	
well	as	CLAD-free	survival	were	constructed	and	the	Log	Rank	test	used	to	assess	significance.	
Factors	 influencing	1-year	mortality	and	early	sepsis	were	assessed	with	single	and	multivariate	Cox	
proportional	hazard	regression	to	calculate	Hazard	Ratios	(HR)	with	95%	confidence	intervals	(95%CI).	
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The	proportional	hazards	assumption	was	confirmed,	taking	p>0.05	upon	generation	of	the	respective	
time-dependent	 covariates.	Multivariate	 Cox	 Regression	 analysis	 used	 forward	 stepwise	 (likelihood	
ratio)	modelling,	taking	p=0.05	and	p=0.10	as	entry	and	removal	cut-offs	at	each	iteration.		
Risk	factors	for	5-year	recurrence	of	malignancy	and	10-year	CLAD	development	were	assessed	using	
competing	risk	regression,	missing	values	being	omitted	over	a	maximum	10	iterations.	
Non-parametric	 tests	were	used	 for	all	variables	and	reported	as	median	 [interquartile	 range	 (IQR)]	
unless	otherwise	stated.	Categorical	variables	were	tested	with	either	Chi2	test	or	Fisher’s	exact	test.	
Continuous	variables	were	analysed	using	Mann-Whitney	U	test	or	Kruskal-Wallis	H	test.	Reported	p-
values	 2-tailed,	 with	 p<0.05	 being	 considered	 significant.	 Analysis	 was	 performed	 using	 IBM	 SPSS	
Statistics	 for	Macintosh,	 Version	 24	 (IBM	 Corp.	 Armonk,	 USA)	 and	 Graphpad	 Prism	 6.0	 (Graphpad	
Software	Inc.,	La	Jolla,	USA).	
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Results	[1370	words]	
In	total,	112	patients	were	identified.	Seven	were	excluded	from	the	analysis,	with	four	considered	to	
have	had	smoking-related	emphysema	and	three	due	to	autologous	rather	than	allogenic	SCT.	Of	the	
105	 patients	 analysed,	 66	 (63%)	 were	 male.	 Median	 age	 at	 LTx	 was	 31.4	 [20.5-43.5]	 years,	 with	
18/105	(17%)	being	<18	years.	AML	was	the	leading	SCT	indication,	comprising	38/105	(36%)	patients.	
Twelve	 patients	 had	 benign	 diseases,	 including	 thalassemia,	 severe	 combined	 immunodeficiency,	
Wiscott-Aldrich	syndrome	and	paroxysmal	nocturnal	haematuria.	Demographic	data	are	summarized	
in	Table	1.		
All	patients	exhibited	advanced	 lung	disease	with	median	FEV1	of	18%	and	FVC	35%	predicted.	Our	
previously	 reported	 clinical	 dichotomy	 in	 LONIPCs	 (4)	 persisted.	 Interstitial	 fibrosis	 was	 found	 in	
51/105	(49%)	explanted	lungs,	corresponding	to	lower	FVC	(31	vs.	45%	predicted;	p=0.005)	and	TLC	
(89	vs.	110%	predicted;	p=0.02)	despite	similar	FEV1	(17	vs.	18%	predicted;	p=0.58)	in	those	patients.	
In	the	absence	of	specific	guidelines	for	LTx	candidate	selection	for	patients	post-SCT,	17/20	centres	
(85%)	reported	adapting	ISHLT	consensus	for	cystic	fibrosis	(colonization,	BMI)	in	conjunction	with	2-
year	cancer-free	interval	prior	to	listing	(22).	Otherwise	no	additional	criteria	were	reported.	In	the	3	
remaining	centres,	 formal	multidisciplinary	collaboration	with	 local	haematologists	was	undertaken,	
to	assure	quiescent	extra-pulmonary	GvHD.		All	centres	reported	monitoring	serum	immunoglobulins	
prior	to	transplant,	with	substitution	only	being	offered	to	those	demonstrating	IgG	deficiency	in	the	
setting	of	≥2	infect	episodes	within	6	months.		
During	both	the	peri-	and	post-LTx	phases,	considerable	variation	in	standard	management	across	the	
20	 centres	 was	 evident,	 due	 in	 part	 to	 variations	 in	 local	 reimbursement	 policies	 across	 the	 12	
jurisdictions	 involved.	 Induction	 therapy	 was	 routinely	 used	 in	 7/20	 centres	 (35%),	 accounting	 for	
35/105	 SCT	 patients	 (33%).	 All	 but	 one	 centre	 used	 the	 same	 agent	 as	 for	 non-SCT	 patients.	 The	
remaining	 centre	 replaced	 their	 standard	 anti-thymocyte	 globulin	 (rATG)	 with	 basiliximab	 due	 to	
physician	 preference.	 In	 total	 21/105	 patients	 (20%)	 received	 basiliximab	 and	 14/105	 (13%)	 rATG.	
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Neither	receipt	of	induction	therapy,	nor	either	of	specific	agents	used	appeared	to	influence	the	risk	
of	sepsis	(HR=	0.83	(0.21-3.29);	p=0.79)	or	early	mortality	(HR=	0.30	(0.04-2.50);	p=0.27).		
All	 centres	 initiated	 standard	 triple	 immunosuppression	post-LTx,	 combining	 a	 calcineurin	 inhibitor,	
anti-metabolite	 and	 steroids.	 The	 commonest	 protocol	 was	 tacrolimus,	 mycophenolate	 and	
prednisolone,	which	was	used	in	79/105	patients	(75%).	In	the	remaining	26	patients	cyclosporine	A	
was	 used,	 7	 of	 whom	 also	 received	 azathioprine	 instead	 of	 mycophenolate	 as	 per	 standard	 local	
policy.	Prednisolone	dosage	of	≤10mg/d	at	4	weeks	post-LTx	was	targeted	at	all	institutions.		
Anti-infective	 prophylaxis	 again	 did	 not	 deviate	 between	 SCT	 and	 non-SCT	 patients	 at	 individual	
centres	 but	 significant	 variation	 between	 institutional	 protocols	 existed.	 Lifelong	 Pneumocystis	
jirovecii	prophylaxis	along	with	 fungal	prophylaxis	 in	 the	 first	4	weeks	was	advocated	by	all	centres.	
Lifelong	systemic	azole	prophylaxis	was	offered	to	only	28/105	patients	(27%).	The	remaining	centres	
reported	 aggressive	 management	 of	 Aspergillus	 species	 if	 detected	 during	 surveillance.	 Reported	
rates	 of	 life-threatening	 fungal	 infections	 among	 the	 SCT	 group	was	 low,	with	 only	 a	 single	 fatality	
reported.	Cytomegalovirus	prophylaxis	again	followed	local	protocols	for	all	patients,	varying	between	
4	weeks	to	12	months	depending	on	the	donor	and	recipient	constellation.					
Total	LTx	volume	at	the	participating	centres	during	the	observation	period	was	10693,	with	current	
centre	volumes	ranging	from	15	–	120	procedures	per	year	(median	40/year).	Median	patient	follow-
up	post-LTx	was	34	[9-75]	months.			
	
Graft	Survival	
Graft	 survival	 at	 1,	 3	 and	 5-years	 post-LTx	 was	 85,	 72	 and	 67%	 respectively.	 Thirty-seven	 patients	
(35%)	died,	with	sepsis	and	CLAD	being	the	leading	causes	of	death.		
Within	 Eurotransplant	 and	 Scandiatransplant	 9,895	 first-time	 LTx	 were	 performed	 between	 1996-
2014.	Using	the	defined	criteria,	4,075	patients	were	 included	 in	the	matched	control	cohort	(Table	
S1).	Given	the	comparatively	young	age	and	high	rates	of	bilateral	LTx	in	the	SCT	cohort,	it	should	be	
noted	 that	 cystic	 fibrosis	 (CF)	 and	 non-CF	 bronchiectasis	were	 disproportionately	 over-represented	
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(32	 vs.	 18%	 of	 registry	 cohort)	 and	 emphysema	 correspondingly	 under-represented	 (29	 vs.	 41%).	
Compared	to	controls,	no	differences	in	graft	survival	at	1,	3	or	5-years	were	evident	(Fig.	1).		
Sixteen	 patients	 (15%)	 died	 within	 12	 months,	 of	 whom	 14	 did	 not	 survive	 to	 hospital	 discharge.	
Sepsis	 accounted	 for	 10	 of	 these	 deaths.	 In	 the	 univariate	 Cox	 Regression	 analysis,	 the	 only	 SCT-
specific	risk	factors	to	achieve	significance	were	prior	calcineurin	inhibitor	treatment	within	6	months	
of	LTx	and	a	time	interval	of	 less	than	24	months	between	the	final	SCT	and	LTX	(Table	2).	Only	the	
latter	 however	 retained	 significance	 in	 the	 subsequent	 multivariate	 analysis	 (HR=	 7.5	 [95%CI:	 2.3-
23.8];	p=0.001),	along	with	FEV1/FVC≥0.7	(HR=5.0	[95%CI:	1.4-17.9];	p=0.012)	and	requiring	inpatient	
care	immediately	prior	to	LTx	(HR=3.4	[95%CI:	1.2-10.0];	p=0.03).			
	
Sepsis		
In	total	15/37	deaths	(41%)	during	the	observation	period	were	attributable	to	sepsis.	Three	deaths	
occurred	 in	 patients	with	 advanced	CLAD	exhibiting	 the	BOS	phenotype.	 Eight	 of	 the	 12	 remaining	
deaths	occurred	peri-operatively,	with	median	 survival	of	42	 [IQR	24-67]	days.	 	Other	 than	a	 single	
case	of	fatal	cytomegalovirus	infection	within	90	days,	no	details	regarding	the	fatal	pathogens	in	the	
remaining	 cases	were	 available.	Only	 2	 had	 reported	 colonization	prior	 to	 LTx,	 being	Pseudomonas	
aeruginosa	(PsA)	and	methicillin-	sensitive	Staphylococcus	aureus	(MSSA)	respectively.			
Univariate	Cox	Regression	 identified	ALL	as	 the	sole	SCT	 risk	 factor	 for	early	 sepsis	 (HR=4.6	 [95%CI:	
1.3-18.7];	 p=0.02),	 alongside	 deteriorating	 native	 lung	 and	 kidney	 function	 and	 increasing	
dependency	 on	 medical	 support	 immediately	 prior	 to	 transplant	 (Table	 S2).	 In	 the	 multivariate	
analysis,	 only	 the	 latter	 retained	 significance	 with	 intensive	 care	 unit	 (ICU)	 admission	 prior	 to	 LTx	
(HR=5.2	 [95%CI:	 1.2-23.4];	 p=0.03),	mechanical	 ventilation	 (HR=6.9	 [95%CI:	 1.0-46.7];	 p<0.001)	 and	
dual-bridging	(HR=7.8	[6.2-98.3];	p=0.001)	being	relevant.		
	
Malignancy	
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Malignancy	accounted	for	8/37	deaths	(22%),	with	all	occurring	among	the	93	patients	with	malignant	
SCT	indications.	Only	half	however	were	due	to	recurrence	of	the	original	malignancy.	AML	accounted	
for	 2	 cases	 in	 whom	 recurrence	 occurred	 within	 12	months	 of	 LTx,	 with	 death	 ensuing	 within	 12	
months	of	diagnosis.	Both	patients	had	received	LTx	within	2	years	of	SCT,	well	below	the	median	72	
[IQR	47-135]	month	interval	in	the	other	34	AML	patients.		
Single	 recurrences	of	ALL	 and	Non-Hodgkin	 Lymphoma	 (NHL)	were	 recorded,	with	 both	presenting	
much	later	at	3	and	5	years	post-LTx	respectively.	Competing	risks	regression	analysis	for	recurrence	
within	5	years	of	LTx	suggested	both	myeloablative	induction	therapy	at	SCT	and	LTx	within	2	years	of	
SCT	as	being	contributory.		
The	 4	 remaining	 fatal	 malignancies	 were	 colorectal	 cancer,	 melanoma	 and	 two	 cases	 of	 PTLD	
unrelated	to	the	primary	malignancy.	Taking	all	eight	malignancies	together,	the	only	significant	risk	
factor	 on	multivariate	Cox	Regression	was	 LTx	within	 24	months	of	 SCT	 (HR:	 6.4	 [95%CI:	 1.3-46.0];	
p=0.03).		
	
Extra-Pulmonary	Chronic	GvHD	
Chronic	GvHD	 involving	other	organs	was	 reported	 in	74/105	patients	 (70%),	with	skin	 involvement	
exhibiting	 the	 highest	 prevalence	 (49%)	 and	 gastrointestinal	 disease	 the	 lowest	 (30%,	 Table	 1).		
Within	 the	 cohort,	neither	 involvement	of	 specific	organs	 (p=0.88)	nor	 cumulative	 site	 involvement	
(p=0.95)	 impacted	on	LTx	survival.	Notably,	 inpatient	LTx	had	 lower	 rates	of	extra-pulmonary	GvHD	
(27	vs.	55%;	p=0.007),	particularly	skin	involvement	(25	vs.	45%;	p=0.03).	No	differences	in	incidence	
regarding	ICU	or	bridging	requirements	were	observed.	
	
Chronic	Lung	Allograft	Dysfunction	and	Re-Transplantation	
CLAD	developed	in	29/79	patients	(37%)	surviving	beyond	the	first	year,	developing	at	median	29	[IQR	
15-56]	months	post-LTx.	Both	CLAD	phenotypes	were	evident,	with	21/29	(72%)	developing	BOS	and	
the	 remaining	 8/29	 (28%)	 rCLAD.	 No	 clear	 relationship	 between	 CLAD	 onset	 or	 phenotype,	 and	
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previous	LONIPC	phenotype	were	evident.	rCLAD	occurred	earlier	(median	13	vs.	47	months;	p=0.002)	
and	 resulted	 in	 earlier	 graft	 loss	 (median	 30	 vs.	 71	 months	 post-LTx;	 p=0.01).	 Limitations	 of	 the	
registry	data	used	for	the	matched	control	cohort	unfortunately	prevented	accurate	comparisons	for	
CLAD-free	 and	 with-CLAD	 survival.	 Broad	 comparisons	 with	 ISHLT	 data	 for	 CLAD-free	 survival,	
dependent	 upon	 surviving	 ≥14	 days	 post-LTx,	 appear	 favourable	 (median	 5.6	 vs.	 11.9	 years)	 but	
interpretation	is	limited.		
Competing	 risks	 regression	analysis	 for	10-year	CLAD	 risk	 identified	only	need	 for	 ICU	 (p=0.02)	 and	
mechanical	ventilation	(p=0.01),	with	no	evidence	of	any	 immunological	associations	between	CLAD	
phenotype	and	previous	GvHD	characteristics.			
Five	redo-LTx	were	performed.	Two	were	attempted	for	primary	graft	dysfunction	(PGD),	with	both	
patients	dying	within	1	week.	CLAD	accounted	for	the	remaining	procedures,	of	which	two	had	rCLAD.	
One	 rCLAD	 patient	 died	 peri-operatively	 due	 to	 bleeding.	 The	 remaining	 two	 redo	 LTx	 patients	
remained	alive	at	study	completion,	12	and	20	months	post-operatively.			
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Discussion	[922	words]	
This	pan-European	experience	of	LTx	as	treatment	for	carefully	selected	candidates	with	life-limiting	
LONIPCs	 following	 allogenic	 stem	 cell	 transplant,	 represents	 the	 largest	 known	 cohort	 of	 such	
patients.	The	most	significant	finding	was	that	survival	at	1,	3	and	5	years	in	this	cohort	was	similar	to	
matched	controls	with	other	end-stage	lung	diseases.		
Given	 the	 current	 reported	 SCT	 volumes	 and	 reported	 incidence	 and	 outcomes	 of	 LONIPCs,	
approximately	 350	 patients	 die	 annually	 in	 Europe	 alone.	 Demonstrating	 the	 feasibility	 of	 LTx	 and	
generating	awareness	 is	 important	for	both	pulmonologists	and	haematologists	alike.	While	unlikely	
that	all	would	be	suitable	LTx	candidates,	the	disparity	to	current	LTx	rates	is	hard	to	ignore.		
These	 findings	provide	encouraging	guidance	 to	LTx	physicians,	assisting	 in	difficult	decision-making	
regarding	candidacy	of	such	patients.	Discouragement	of	orphan	diseases	is	an	inherent	limitation	of	
organ	allocation	systems.	With	the	intent	of	optimizing	graft	utility,	their	reliance	on	1-year	outcome	
data	 tends	 to	 discriminate	 when	 a	 critical-mass	 of	 data	 does	 not	 exist.	 Furthermore,	 the	 body	 of	
evidence	available	appears	to	suggest	that	such	carefully	selected	patients	can	be	managed	in	a	very	
similar	fashion	to	other	LTx	recipients,	without	affecting	outcomes.		
Being	a	 retrospective	analysis	 involving	numerous	 centres	of	 varying	 LTx	experience,	 it	 is	 inevitable	
given	the	condition’s	reputation	that	cautious	decision-making	resulted	in	candidate	selection	bias	at	
listing.	 Young	 recipient	age,	high	outpatient	 LTx	 rates	and	 lack	of	 comorbidities	among	hospitalized	
patients	are	all	 suggestive.	 Ideally,	consideration	of	rejected	candidate	referrals	and	wait-list	deaths	
would	 add	 value	 to	 the	 analysis,	 but	 obtaining	 data	 from	 all	 centres	 proved	 unfeasible.	 While	
minimizing	inter-observer	variability,	use	of	standardized	data	collection	enforced	a	“lowest	common	
denominator”	 approach	 to	 maximize	 completeness,	 generating	 more	 qualitative	 data.	 For	 certain	
aspects,	such	as	treatment	exposure	or	extent	of	disease,	greater	reliance	on	quantitative	data	may	
have	proved	more	insightful.	
Due	caution	 is	encouraged	 in	 interpreting	the	Cox	Proportional	Hazard	models	given	the	 infrequent	
events	within	a	small	cohort.	The	spread	in	the	95%	confidence	intervals	reflect	this,	casting	a	degree	
Original	Research	
European	Respiratory	Journal		
	
	 14	
of	 uncertainty	 that	 can	 only	 be	 resolved	 with	 increasing	 case	 volume.	 As	 such,	 the	 results	 reflect	
current	experience	 to	assist	physicians	 facing	difficult	decision-making	when	assessing	or	managing	
such	patients.		
Nonetheless,	the	findings	provide	an	important	insight	into	the	factors	impacting	upon	early	survival,	
and	dispel	some	of	the	common	concerns	about	sepsis	risk	and	recurring	malignancy.	The	relevance	
of	1-year	all-cause	mortality	 is	rooted	in	allocation	policies.	Apart	from	LTx	within	2	years	of	SCT,	all	
the	identifiable	risk-factors	in	the	uni-	and	multivariate	analysis	reflected	the	general	clinical	condition	
and	as	highlighted	in	the	ISHLT	Registry,	are	by	no	means	exclusive	to	LONIPCs	(9).	Interestingly,	the	
recent	 recognition	 of	 LONIPC	 phenotypes	 appears	 relevant,	 as	 those	 with	 restrictive	 spirometry	
(FEV1/FVC	≥70%:	HR	5.0	 [95%CI:	 1.4-17.9];	p=0.012)	 exhibited	poorer	 early	 survival	 on	multivariate	
analysis.	 It	 is	 however	 unclear	 if	 this	 reflects	 patient	 condition	 or	 the	 duration	 of	 prior	
immunosuppression	 which,	 as	 stated	 previously	 (4),	 was	 significantly	 longer	 among	 patients	 with	
restrictive	lung	function	(54	[30-108]	vs.	114	[70-152]	months;	p=0.002).			
Early	fatal	sepsis	accounted	for	8/17	deaths	(47%),	which	appears	to	exceed	(192/781	deaths;	25%)	
ISHLT	Registry	reports	(9).	Except	for	ALL,	no	other	SCT-specific	factors	were	identified.	Caution	due	
to	the	small	numbers	 involved	is	again	advised,	but	4/16	LTx	recipients	with	a	history	of	ALL	died	of	
early	sepsis,	accounting	for	half	of	such	deaths.	No	clear	explanation	was	evident,	but	it	is	noteworthy	
that	sepsis-related	death	is	problematic	among	ALL	patients	following	SCT	(23)	with	immunoglobulin	
deficiencies	 being	 implicated	 (24).	 Importantly	 however,	 concerns	 related	 to	 prior	
immunosuppression	or	microbial	airway	colonization	could	not	be	substantiated.	The	consensus	view	
among	 the	authors	was	 that	colonization	should	not	 represent	an	absolute	contraindication,	 rather	
remain	an	 individual-case	consideration.	 It	 should	be	noted	however,	 that	none	of	 the	cohort	were	
colonized	 with	 more	 contentious	 pathogens	 such	 as	 Mycobacterium	 abcessus,	 Scedosporium	 or	
Burkholderia	species.		
Recurrence	 rates	 of	 primary	 malignancy	 were	 low	 at	 4%.	 Given	 the	 small	 numbers	 involved	 and	
proportionately	large	number	of	early	deaths	of	alternative	cause,	concealed	confounders	are	likely.	
Original	Research	
European	Respiratory	Journal		
	
	 15	
To	compensate	for	this	a	competing	risks	regression	was	used,	 identifying	LTx	within	2	years	of	 last	
SCT	as	the	only	risk	factor.	While	AML	data	appears	to	support	this,	the	interaction	between	factors	
remains	 unclear	 and	 should	 be	 considered	 in	 context.	 Current	 candidate	 selection	 guidelines	
recommend	 a	malignancy-free	 interval	 of	 2	 years	 for	 all	 LTx(22)	 and	 given	 all-cause	mortality	 data	
presented	here	(Fig.	2),	no	clear	evidence	to	the	contrary	can	be	provided.		
Extra-pulmonary	chronic	GvHD	causes	considerable	comorbidity	and	its	lack	of	influence	on	outcomes	
suggests	inadequacy	of	data.	Concerns	regarding	inadequate	nutrition	or	oral	immunosuppression	in	
gastrointestinal	GvHD,	should	be	considered	analogous	with	those	in	cystic	fibrosis	where	attainment	
of	stable	body	mass	with	or	without	enteral	feeding	represents	a	basic	LTx	requirement	(22).		
Given	their	similarities,	both	 in	terms	of	end-organ	damage	and	unpredictable	responses	to	broadly	
similar	treatment	strategies,	the	development	of	host	vs.	graft	CLAD	in	patients	with	existing	graft	vs.	
host	 disease	 is	 somewhat	 unique.	 Unfortunately,	 no	 associations	 regarding	 incidence,	 timing	 or	
phenotypic	 recurrence	 were	 found.	 Furthermore,	 there	 was	 nothing	 in	 the	 observed	 CLAD	
demographics	to	suggest	substantial	deviation	from	reported	patterns	in	other	disease	groups.			
In	 conclusion,	 LTx	 is	 a	 feasible	 treatment	 option	 for	 refractory	 LONIPCs	 in	 thoroughly	 evaluated,	
carefully	 selected	 candidates,	 with	 comparable	 survival	 rates	 to	 other	 indications.	 Accurate	
characterization	 of	 LONIPCs	 and	 timely	 referral	 appear	 important	 in	 minimizing	 risk.	 Candidate	
evaluation,	 selection	 and	 peri-operative	 care	 should	 adhere	 to	 similar	 local	 protocols	 and	 values	
afforded	to	other	end-stage	lung	diseases.	
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Patient	Demographics	 	
	 	N	 105	 	
	 	Male,	N	(%)	 66	 (63)	
	 	Age	at	LTx,	years	 31.4	 [20.5	–	43.5]	
	 		-	Patients	<18years,	N	(%)	 18	 (17)	
	 	Never-smoker,	N	(%)	 88	 (84)	
	 FEV1	%Predicted	 18	 [15-21]	
	 FVC	%Predicted	 35	 [25-48]	
	 TLC	%Predicted	 103	 [74-119]	
	 Restrictive	GvHD	Phenotype,	N	(%)	 51	 (49)	
	 Airway	Colonization,	N	(%)	 39	 (37)	
	 -	Pseudomonas	aeruginosa,	N	(%)	 20	 (19)	
	 -	Aspergillus	fumigatus,	N	(%)	 8	 (8)	
	 	eGFR	(CKD-EPI),	ml/min/1.73m2	 93.1	 [84.5-119.3]	
	 	 	 	
Stem	Cell	Transplantation		 	
	 Indication	 	 	
	 	AML,	N	(%)	 38	 (36)	
	 	ALL,	N	(%)	 16	 (15)	
	 	CML,	N	(%)	 18	 (17)	
	 	CLL,	N	(%)	 2	 (2)	
	 	Non-Hodgkin	Lymphoma,	N	(%)	 6	 (6)	
	 	Hodgkin	Lymphoma,	N	(%)	 6	 (6)	
	 	Myelodysplastic	Syndrome,	N	(%)	 7	 (7)	
	 	Non-malignant	disease,	N	(%)	 12	 (11)	
	 Type	 	 	
	 	Bone	Marrow,	N	(%)	 51	 (49)	
	 	Peripheral	Blood,	N	(%)	 54	 (51)	
	 	Age	at	first	SCT,	years	 22.7	 [14.4	–	36.3]	
	 				>1	SCT	attempts,	N	(%)	 6	 (6)	
	 	Timing	SCT	after	diagnosis,	months	 11.2	 [4.5	–	21.0]	
	 Conditioning	Treatment	 	 	
	 	Reduced-intensity,	N	(%)	 16	 (18)	
	 	Myeloablative,	N	(%)	 87	 (83)	
	 			-	Busulphan,	N	(%)	 32	 (35)	
	 			-	Cyclophosphamide,	N	(%)	 47	 (52)	
	 			-	Fludarabine,	N	(%)	 20	 (22)	
	 			-	Melphalan,	N	(%)	 17	 (19)	
	 	Total	Body	Irradiation#,	N	(%)	 46	 (53)	
	 	 	 	
Graft-versus-Host	Disease	 	 	
	 	Involvement	of	any	extra-pulmonary	site,	N	(%)	 74	 (70)	
	 	Skin,	N	(%)	 52	 (49)	
	 	Gastrointestinal,	N	(%)	 31	 (30)	
	 	Ocular,	N	(%)	 33	 (31)	
	 	Mucosal,	N	(%)	 43	 (41)	
	 	No.	of	extra-pulmonary	sites	 2	 [0-3]	
	 Treatment		 	 	
	 	Ciclosporine,	N	(%)	 75	 (71)	
	 	Steroid,	N	(%)	 68	 (65)	
	 	Mycophenolate,	N	(%)	 31	 (30)	
	 	Methotrexate,	N	(%)	 18	 (17)	
	 	No.	GvHD	treatments	at	LTx	 2	 [2-3]	
	 	 	 	
Lung	Transplantation	 	 	
	 Bilateral	LTx,	N	(%)	 89	 (85)	
	 Timing	LTx	after	SCT,	months	 69	 [36-122]	
	 -	LTx	<2	years	post-SCT,	N	(%)	 15	 (14)	
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	 Induction,	N	(%)	 35	 (33)	
	 Inpatient,	N	(%)	 38	 (36)	
	 Intensive	Care,	N	(%)	 23	 (22)	
	 -	Mechanical	Ventilation	only,	N	(%)	 14	 (13)	
	 -	ECMO	only,	N	(%)	 5	 (5)	
	 -	Combined	Mechanical	Ventilation	&	ECMO,	N	(%)	 4	 (4)	
	 Inpatient	Stay	post-LTx,	days	 37	 [23-71]	
	 Patient	Follow-Up	post	LTx,	months	 34	 [9-75]	
	 	 	 	
Table	1:	 Summary	of	 stem	cell	 transplant	 (SCT)	patient	demographics,	 including	 treatment	up	 to	and	 including	
lung	 transplantation	 (LTx).	 	 Values	 are	 median	 [interquartile	 range]	 unless	 otherwise	 stated.	 Key:	 ALL:	 acute	
lymphoblastic	leukemia;	AML:	acute	myeloid	leukemia;	CLL:	chronic	lymphocytic	leukemia;	CML:	chronic	myeloid	
leukemia;	ECMO:	extracorporeal	membrane	oxygenation;	eGFR:	estimated	Glomerular	Filtration	Rate,	calculated	
using	 the	 CKD-EPI	 (2012)	 Formula(25);	 FEV1:	 Forced	 expiratory	 volume	 in	 1s;	 FVC:	 Forced	 vital	 capacity;	 rATG:	
Anti-thymocyte	Globulin	and	TLC:	Total	lung	capacity	*Data	available	for	91pts.	#Data	available	for	86pts.	
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All	Cause	1yr	Mortality	 N	 Proportional	Hazard	
Univariate	Analysis	 Multivariate	Analysis	
HR	 (95%	CI)	 p	 HR	 (95%	CI)	 p	
Demographics	 	 	 	 	 	 	 	 	
	 Male	 66	 0.71	 2.59	 (0.90-7.42)	 0.08	 	 	 	
	 Never-Smoker	 89	 0.92	 0.45	 (0.13-1.54)	 0.20	 	 	 	
	 Age	per	10y	increase	 105	 0.18	 1.08	 (0.74-1.55)	 0.70	 	 	 	
	 FEV1	per	10%	pred	loss	 105	 0.43	 1.12	 (0.64-1.89)	 0.43	 	 	 	
	 FVC	per	10%	pred	loss	 105	 0.44	 5.14	 (1.21-21.88)	 0.03	 	 	 	
	 FEV1/FVC	≥0.7	 92	 0.32	 1.45	 (0.27-7.90)	 0.67	 5.04	 (1.42-17.90)	 0.012	
	 TLC	≤90%	predicted	 16	 0.55	 0.40	 (0.14-1.15)	 0.09	 	 	 	
	 Isolated	BO	on	CT	 54	 0.95	 0.79	 (0.28-2.24)	 0.65	 	 	 	
	 Colonized	 39	 0.67	 1.18	 (0.29-4.78)	 0.81	 	 	 	
	 -	PsA	 20	 0.27	 2.43	 (0.23-15.43)	 0.46	 	 	 	
	 -	Aspergillus	 8	 0.61	 0.86	 (0.09-8.65)	 0.89	 	 	 	
	 eGFR	<90ml/min	 65	 0.53	 1.45	 (0.54-3.96)	 0.46	 	 	 	
	 	 	 	 	 	 	 	 	 	
Primary	Diagnosis	 	 	 	 	 	 	 	 	
	 AML	 38	 0.59	 1.09	 (0.91-1.33)	 0.41	 	 	 	
	 ALL	 16	 0.49	 1.95	 (0.54-6.98)	 0.29	 	 	 	
	 CML	 18	 0.57	 0.93	 (0.77-1.13)	 0.73	 	 	 	
	 CLL	 2	 0.86	 1.69	 (0.42-6.77)	 0.30	 	 	 	
	 NHL	 6	 0.50	 1.04	 (0.69-1.45)	 0.97	 	 	 	
	 HL	 6	 0.47	 1.01	 (0.11-9.48)	 1.00	 	 	 	
	 MDS	 7	 1.00	 0.83	 (0.76-0.91)	 0.59	 	 	 	
	 Benign	 12	 0.99	 0.82	 (0.74-0.90)	 0.21	 	 	 	
	 	 	 	 	 	 	 	 	 	
Stem	Cell	Transplant	 	 	 	 	 	 	 	 	
	 BMT	 51	 0.32	 0.38	 (0.13-1.09)	 0.07	 	 	 	
	 Multiple	SCT	 6	 0.62	 0.95	 (0.12-7.91)	 0.96	 	 	 	
	 SCT-LTx	2yrs	 15	 0.44	 3.32	 (1.19-9.23)	 0.02	 7.46	 (2.33-23.84)	 0.001	
	 Myeloablation	 87	 0.69	 1.46	 (0.19-11.11)	 0.71	 	 	 	
	 -	Busulphan	 32	 0.58	 1.07	 (0.27-4.26)	 0.93	 	 	 	
	 -	Cyclophosphamide	 47	 0.40	 1.40	 (0.35-5.61)	 0.63	 	 	 	
	 Total	Body	Irradiation	 46	 0.92	 1.75	 (0.60-5.14)	 0.31	 	 	 	
	 	 	 	 	 	 	 	 	 	
Extra-Pulmonary	GvHD	 	 	 	 	 	 	 	 	
	 GvHD	Skin	 52	 0.29	 1.56	 (0.55-4.44)	 0.41	 	 	 	
	 GvHD	GI	 31	 0.60	 1.35	 (0.42-4.38)	 0.62	 	 	 	
	 GvHD	Eye	 33	 0.12	 3.46	 (0.83-14.51)	 0.09	 	 	 	
	 GvHD	Mucosa	 43	 0.50	 2.23	 (0.70-7.04)	 0.18	 	 	 	
	 Calcineurin	Inhibitor	<6mts	 75	 0.33	 2.95	 (0.99-8.82)	 0.05	 	 	 	
	 Mycophenolate	<6mts	 31	 0.90	 0.68	 (0.23-2.02)	 0.48	 	 	 	
	 Systemic	Steroids	<6mts	 68	 0.57	 0.86	 (0.15-3.07)	 0.62	 	 	 	
	 	 	 	 	 	 	 	 	 	
Peri-LTx	Treatment	 	 	 	 	 	 	 	 	
	 DLTx	 89	 0.69	 0.54	 (0.33-0.89)	 0.02	 	 	 	
	 Induction	 35	 0.36	 0.30	 (0.04-2.50)	 0.27	 	 	 	
	 Inpatient	at	LTx	 38	 0.45	 4.46	 (1.23-16.15)	 0.02	 3.40	 (1.16-10.01)	 0.03	
	 ICU	 23	 0.36	 0.78	 (0.12-5.27)	 0.80	 	 	 	
	 MV	 14	 0.23	 8.47	 (2.36-37.19)	 <0.001	 	 	 	
	 ECMO	 5	 0.48	 5.08	 (0.50-31.81)	 0.17	 	 	 	
	 Dual	Bridging	 4	 0.44	 10.80	 (1.60-42.75)	 0.02	 	 	 	
	 	 	 	 	 	 	 	 	 	
Table	2:	Uni-	and	multivariate	Cox	regression	analysis	assessing	risk	factors	for	all-cause	mortality	≤12	months	after	lung	transplantation	
(LTx).	Hazard	ratio	(HR)	with	95%	confidence	intervals	(95%CI).	Key:	FEV1	–	forced	expiratory	volume	in	1s,	FVC	–	forced	vital	capacity,	
TLC	 –	 total	 lung	 capacity,	 BO	 –	 bronchiolitis	 obliterans,	 CT	 –	 computerized	 tomography,	 PsA	 –	 Pseudomonas	 aeruginosa,	 GFR	 –	
estimated	glomerular	filtration	rate	(calculated	using	CKD-EPI),	AML:	acute	myeloid	leukemia;	ALL:	acute	lymphoblastic	leukemia;	CML:	
chronic	 myeloid	 leukemia;	 CLL:	 chronic	 lymphocytic	 leukemia;	 NHL	 –	 non-Hodgkin	 lymphoma,	 HL	 –	 Hodgkin	 lymphoma,	 MDS	 –	
myelodysplastic	syndrome,	BMT	–	bone	marrow	transplantation,	SCT	–	stem	cell	transplantation,	TBI	–	total	body	irradiation,	GvHD	–	
graft	vs.	host	disease,	ICU	–	intensive	care	unit,	MV	–	mechanical	ventilation	and	ECMO	–	extracorporeal	membranous	oxygenation.		
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	 Fig.1	Kaplan	Meier	Curve	showing	graft	survival	following	1st	LTx	among	SCT	patients	as	well	as	matched	controls	from	the	other	
main	disease	groups.	Comparing	SCT	vs.	non-SCT	patients,	no	differences	in	survival	were	observed	at	1,	3	and	5	years	post-LTx.	
Key:	SCT:	allogeneic	stem	cell	transplant;	CF:	cystic	fibrosis;	NCFB:	non-cystic	fibrosis	bronchiectasis.		
	
	
	
	
Fig.2	 Kaplan	Meier	 Curve	 showing	 graft	 survival	 following	 1st	 LTx	 among	 SCT	 patients,	 dependent	 upon	 the	 time	 interval	 between	
procedures.	 Early	 survival	 was	 worse	 in	 those	 proceeding	 to	 LTx	 within	 2	 years	 of	 SCT,	 but	 beyond	 the	 first	 year	 no	 differences	
remained.	Key:	LTx:	lung	transplantation;	SCT:	allogeneic	stem	cell	transplant;	yrs:	years.	
	
	


	 	 	 SCT Controls Emphysema Fibrosis CF/NCFB Other 
Patients              
	 Pre-matching,	N	(%)	 105	 9,895	 4014	 (41)	 2368	 (24)	 1815	 (18)	 1698	 (17)	
	 Post-matching,	N	(%)	 105	 4,075	 1183	 (29)	 911	 (22)	 1303	 (32)	 678	 (17)	
	 Male,	N	(%)	 	 66	 (63)	 2381	 (58)	 726	 (61)	 626	 (68)	 695	 (53)	 334	 (49)	
	 Age	LTx,	years	 31	 21-43	 43	 27-54	 55	 49-59	 50	 41-58	 26	 21-33	 34	 23-46	
	 DLTx,	N	(%)	 	 89	 (85)	 3268	 (80)	 789	 (67)	 604	 (66)	 1272	 (98)	 603	 (89)	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Status at LTx 	 	 	 	 	 	 	 	 	 	 	 	
	 Elective,	N	(%)	 67	 (64)	 2919	 (72)	 1055	 (89)	 620	 (68)	 807	 (62)	 437	 (64)	
	 Urgent,	N	(%)	 15	 (14)	 127	 (3)	 35	 (3)	 33	 (4)	 44	 (3)	 15	 (2)	
	 High-Urgent,	N	(%)	 23	 (22)	 1029	 (25)	 93	 (8)	 258	 (28)	 452	 (35)	 226	 (34)	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Supp.	Table	1:	Summary	of	the	control	cohort.	Demographic	data	relates	to	matched	controls	only.	Values	are	median	[interquartile	range]	
unless	otherwise	stated.	Key:	LTx:	lung	transplantation;	DLTx:	bilateral	lung	transplantation;	SCT:	allogeneic	stem	cell	transplant;	CF:	cystic	
fibrosis;	NCFB:	non-cystic	fibrosis	bronchiectasis.	
	 	
Early	Sepsis	Risk	 N	 Proportional	Hazard	
Univariate	Analysis	 Multivariate	Analysis	
HR	 (95%	CI)	 p	 HR	 (95%	CI)	 p	
Demographics	 	 	 	 	 	 	 	 	
	 Male	 66	 0.73	 1.08	 (0.96-1.21)	 0.21	 	 	 	
	 Never-Smoker	 89	 0.20	 1.13	 (0.89-1.45)	 0.18	 	 	 	
	 Age	per	10y	increase	 105	 0.11	 1.14	 (0.83-1.57)	 0.41	 	 	 	
	 FEV1	per	10%	pred	loss	 105	 0.68	 1.36	 (1.02-3.31)	 0.03	 	 	 	
	 FVC	per	10%	pred	loss	 105	 0.38	 3.61	 (1.32-13.91)	 0.01	 	 	 	
	 FEV1/FVC	≥0.7	 92	 0.83	 2.52	 (1.71-4.63)	 0.05	 4.26	 (1.01-17.97)	 0.04	
	 TLC	≤90%	predicted	 16	 0.91	 0.67	 (0.14-3.14)	 0.61	 	 	 	
	 Isolated	BO	on	CT	 54	 0.55	 0.58	 (0.16-2.06)	 0.40	 	 	 	
	 Colonized	 39	 0.25	 1.82	 (0.29-14.59)	 0.57	 	 	 	
	 -	PsA	 20	 0.46	 1.38	 (0.09-22.03)	 0.82	 	 	 	
	 -	Aspergillus	 8	 0.99	 1.13	 (0.84-1.42)	 0.98	 	 	 	
	 eGFR	<90ml/min	 65	 0.57	 3.77	 (1.03-14.55)	 0.04	 	 	 	
	 	 	 	 	 	 	 	 	 	
Primary	Diagnosis	 	 	 	 	 	 	 	 	
	 AML	 38	 0.89	 0.93	 (0.83-1.04)	 0.32	 	 	 	
	 ALL	 16	 0.65	 4.61	 (1.34-18.74)	 0.02	 	 	 	
	 CML	 18	 0.19	 1.23	 (0.24-6.36)	 0.68	 	 	 	
	 CLL	 2	 0.98	 1.83	 (0.46-7.31)	 0.18	 	 	 	
	 NHL	 6	 0.54	 1.37	 (0.18-10.79)	 0.19	 	 	 	
	 HL	 6	 0.99	 0.90	 (0.84-1.04)	 0.59	 	 	 	
	 MDS	 7	 1.00	 0.93	 (0.81-1.12)	 0.54	 	 	 	
	 Benign	 12	 0.99	 0.89	 (0.73-1.02)	 0.42	 	 	 	
	 	 	 	 	 	 	 	 	 	
Stem	Cell	Transplant	 	 	 	 	 	 	 	 	
	 BMT	 51	 0.31	 0.55	 (0.16-1.95)	 0.35	 	 	 	
	 Multiple	SCT	 6	 1.00	 1.10	 (0.84-1.21)	 0.59	 	 	 	
	 SCT-LTx	2yrs	 15	 0.32	 2.12	 (0.55-8.19)	 0.28	 	 	 	
	 Myeloablation	 87	 0.71	 2.82	 (0.35-22.55)	 0.33	 	 	 	
	 -	Busulphan	 32	 0.46	 1.06	 (0.15-7.54)	 0.95	 	 	 	
	 -	Cyclophosphamide	 47	 0.97	 1.85	 (0.31-11.09)	 0.48	 	 	 	
	 Total	Body	Irradiation	 46	 0.23	 2.97	 (0.62-14.43)	 0.17	 	 	 	
	 	 	 	 	 	 	 	 	 	
Extra-Pulmonary	GvHD	 	 	 	 	 	 	 	 	
	 GvHD	Skin	 52	 0.99	 1.02	 (0.27-3.86)	 0.98	 	 	 	
	 GvHD	GI	 31	 0.90	 0.76	 (0.19-3.01)	 0.70	 	 	 	
	 GvHD	Eye	 33	 0.64	 3.35	 (0.43-26.17)	 0.43	 	 	 	
	 GvHD	Mucosa	 43	 0.51	 1.20	 (0.30-4.77)	 0.79	 	 	 	
	 Calcineurin	Inhibitor	<6mts	 75	 0.57	 3.26	 (0.78-13.67)	 0.11	 	 	 	
	 Mycophenolate	<6mts	 31	 0.35	 0.94	 (0.23-3.95)	 0.94	 	 	 	
	 Systemic	Steroids	<6mts	 68	 0.63	 1.27	 (0.26-6.29)	 0.77	 	 	 	
	 	 	 	 	 	 	 	 	 	
Peri-LTx	Treatment	 	 	 	 	 	 	 	 	
	 DLTx	 89	 0.87	 0.54	 (0.12-2.44)	 0.35	 	 	 	
	 Induction	 35	 0.30	 0.83	 (0.21-3.29)	 0.79	 	 	 	
	 Inpatient	at	LTx	 38	 0.19	 4.93	 (1.24-19.07)	 0.012	 	 	 	
	 ICU	 23	 0.92	 4.37	 (1.27-15.12)	 0.02	 5.19	 (1.15-23.43)	 0.03	
	 MV	 14	 0.44	 6.41	 (1.85-22.23)	 0.003	 6.92	 (1.03-46.71)	 <0.001	
	 ECMO	 5	 0.68	 5.39	 (1.14-25.54)	 0.05	 	 	 	
	 Dual	Bridging	 4	 0.55	 13.01	 (5.67-56.19)	 0.007	 7.79	 (6.17-98.31)	 0.001	
	 	 	 	 	 	 	 	 	 	
Supp	Table	2:	Uni-	and	multivariate	Cox	regression	analysis	assessing	risk	factors	for	early	sepsis	(≤12	months)	after	lung	transplantation	
(LTx).	Hazard	ratio	(HR)	with	95%	confidence	intervals	(95%CI).	Key:	FEV1	–	forced	expiratory	volume	in	1s,	FVC	–	forced	vital	capacity,	TLC	–	
total	lung	capacity,	BO	–	bronchiolitis	obliterans,	CT	–	computerized	tomography,	PsA	–	Pseudomonas	aeruginosa,	GFR	–	estimated	
glomerular	filtration	rate	(calculated	using	CKD-EPI),	AML:	acute	myeloid	leukemia;	ALL:	acute	lymphoblastic	leukemia;	CML:	chronic	
myeloid	leukemia;	CLL:	chronic	lymphocytic	leukemia;	NHL	–	non-Hodgkin	lymphoma,	HL	–	Hodgkin	lymphoma,	MDS	–	myelodysplastic	
syndrome,	BMT	–	bone	marrow	transplantation,	SCT	–	stem	cell	transplantation,	TBI	–	total	body	irradiation,	GvHD	–	graft	vs.	host	disease,	
ICU	–	intensive	care	unit,	MV	–	mechanical	ventilation	and	ECMO	–	extracorporeal	membranous	oxygenation.	
